Another nail has been hammered into the coffin of the pharma model of providing lavish entertainment and other benefits to doctors to encourage prescribing of medicines.
Novartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused on activities in Greece and other countries, for $347 mi
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh